Arnot Ogden Medical Center Family Medicine

Topics

• Lung Cancer Treatments and Mutations 7
• Innovations in Medical Education 5
• Chronic Myeloid Leukemia Treatments 4
• HER2/EGFR in Cancer Research 4
• Venous Thromboembolism Diagnosis and Management 4
• Acute Myeloid Leukemia Research 3
• Dermatological and Skeletal Disorders 3
• Diversity and Career in Medicine 3
• Cerebrospinal fluid and hydrocephalus 2
• Cerebrovascular and Carotid Artery Diseases 2
• Fetal and Pediatric Neurological Disorders 2
• Glioma Diagnosis and Treatment 2

Most cited

1. HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy.

   Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023 · 226 citations · David Sternberg

2. Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer.

   Cancer discovery · 2022 · 262 citations · David Sternberg

3. Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3-Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3-Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial.

   Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023 · 128 citations · David Sternberg

4. HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced EGFR-mutated NSCLC after a third-generation EGFR TKI.

   Future oncology (London, England) · 2024 · 60 citations · David Sternberg

5. Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC.

   Annals of oncology : official journal of the European Society for Medical Oncology · 2024 · 46 citations · David Sternberg